| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-12-04 |
Boehringer Ingelheim (Germany) Domain Therapeutics (France) |
orphan G Protein-Coupled Receptors (GPCRs) |
|
research - licensing |
CNS diseases |
Licensing agreement |
| 2018-12-04 |
Lundbeck (Denmark) |
|
|
resignation |
|
Resignation |
| 2018-11-29 |
BMS (USA - NY) the Francis Crick Institute (UK) Cancer Research UK (UK) |
RUBICON, a rule book and immune atlas for combination therapy |
lung cancer |
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2018-11-26 |
Intrasense (France) 12 Sigma Technologies (USA - CA) |
?Discover Lung Nodule, Artificial Intelligence-based Computer Aided Diagnostics (CAD) solutions |
lung cancer |
collaboration |
Technology - Services |
Collaboration agreement |
| 2018-11-26 |
RegenXBio (USA - MD) Rocket Pharmaceuticals (USA - NY) |
NAV AAV9 vector and two additional NAV AAV vectors |
Danon disease |
licensing |
Rare diseases - Genetic diseases - Cardiovascular diseases - Neuromuscular diseases |
Licensing agreement |
| 2018-11-20 |
Santhera Pharmaceuticals (Switzerland) Idorsia (Switzerland) |
VBP15 (vamorolone) |
Duchenne muscular dystrophy |
licensing
|
Rare diseases - Genetic diseases - Neuromuscular diseases |
Licensing agreement |
| 2018-11-14 |
Nektar Therapeutics (USA - CA) |
vice president |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-11-12 |
Integragen (France) Google Cloud (USA - CA) |
SIRIUS™ and MERCURY™ |
|
collaboration |
Technology - Services |
Collaboration agreement |
| 2018-11-10 |
Abbvie (USA - IL) Sandoz (Switzerland) |
- intellectual property relating to Humira®
|
plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa, non-infectious uveitis |
licensing
- biosimilar/monoclonal antibody/TNF alpha inhibitor. Adalimumab is a monoclonal antibody that binds specifically to TNF alpha and blocks its interaction with cell surface TNF receptors. It is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
|
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Dermatological diseases |
Licensing agreement |
| 2018-11-05 |
Actelion (Switzerland), now Idorsia (Switzerland) ReveraGen BioPharma (USA - MD) |
vamorolone |
Duchenne muscular dystrophy |
licensing |
Rare diseases - Genetic diseases - Neuromuscular diseases |
Licensing agreement |
| 2018-11-01 |
Denali Therapeutics (USA - CA) Sanofi (France) |
RIPK1 inhibitor molecules including DNL747 and DNL758 |
Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and systemic inflammatory diseases as rheumatoid arthritis and psoriasis. |
development - licensing - commercialisation |
Neurodegenerative diseases - Inflammatory diseases - Autoimmune diseases |
Development agreement |
| 2018-10-31 |
Novo Nordisk (Denmark) Strongbridge Biopharma (Ireland) |
US and Canadian rights to Macrilen™ (macimorelin)
|
adult growth hormone deficiency (AGHD) |
licensing |
Rare diseases - Endocrine diseases - Hormonal diseases |
Licensing agreement |
| 2018-10-31 |
MeiraGTx (USA - NY) National Institute of Dental and Craniofacial Research (NIDCR) (USA) |
AAV-AQP1 |
Sjögren’s syndrome and associated xerostomia or xerophthalmia |
licensing |
Rare diseases |
Licensing agreement |
| 2018-10-30 |
Transgene (France) NEC (Japan) |
myvac™ and Neoantigen Prediction System |
solid tumors including ovarian cancer and HPV-negative head and neck cancer |
collaboration |
Cancer - Oncology |
Collaboration agreement |
| 2018-10-29 |
Ionis Pharmaceuticals (USA - CA) ProQR Therapeutics (The Netherlands) |
QR-1123 (formerly “IONIS-RHO-2.5Rx”) |
autosomal dominant retinitis pigmentosa caused by the P23H mutation in the rhodopsin (RHO) gene (P23H adRP) |
licensing |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Licensing agreement |
| 2018-10-25 |
89Bio (USA - CA) |
CEO -CSO - COO - CBO - member of the board of directors |
|
nomination |
Hepatic diseases - Liver diseases |
Restructuring |
| 2018-10-25 |
Disarm Therapeutics (USA - MA) |
member of the board of directors |
|
nomination |
Neurological diseases - Neurodegenerative diseases |
Nomination |
| 2018-10-23 |
Cryoport (USA - CA) |
global logistics center in Livingston |
|
opening of new premises |
Technology - Services |
Opening of new premises |
| 2018-10-22 |
RegenXBio (USA - MD) Ultragenyx Pharmaceutical (USA - CA) |
adeno-associated virus (AAV) vectors, including AAV9 |
CDKL5 deficiency disorder |
licensing |
Rare diseases - Genetic diseases - Neurological diseases |
Licensing agreement |
| 2018-10-18 |
Abbvie (USA - IL) Fresenius Kabi (Germany) |
MSB11022 - biosimilar version of Humira® (adalimumab) |
|
licensing |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases |
Licensing agreement |
